-
Rituximab (mabthera®) : a new therapy for anca vasculitis
Von frenckell C. , Delanaye P.
Rev Med Liege 2015, 70(2),92-100Abstract : Three recently published randomized studies have demonstrated the efficacy of rituximab in the induction and maintenance therapy of anca vasculitis. This is a major advance since these types of vasculitis entail a high morbity and mortality. Keywords :Vvasculitis - Anti-neutrophil cytoplasm antibody - Granulomatosis with polyangeitis - Microscopic polyangeitis - B cell - Biologic therapy – Rituximab
